Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the BCR::ABL1 fusion protein resulting in the uncontrolled production of granulocytes.1 In 2022 it was estimated that approximately 8860 people would be diagnosed with CML in the United States.2 Tyrosine kinase inhibitors (TKIs) have dramatically improved the 10-year survival rate of patients with CML from 20% to 80%.3-5 There are four TKIs approved by the US Food and Drug Administration as first-line (1L) therapy for treating patients who have CML: imatinib (2000), dasatinib (2006), nilotinib (2007), and bosutinib (2012).

Source: Clinical Lymphoma, Myeloma and Leukemia - October 19, 2023 Category: Hematology Authors: Andrew J. Klink, Scott J. Keating, John Brokars, Bruce Feinberg, Elias Jabbour Tags: Original Study Source Type: research